A new experimental pill called daraxonrasib has shown promising results in advanced pancreatic cancer patients, nearly doubling survival time compared to chemotherapy. Researchers say the targeted drug blocks a key cancer-driving mutation found in most pancreatic tumours. Experts believe the breakthrough could transform treatment options for one of the world's deadliest cancers.